Get the Stockscreener App
227.01
0.19%
-0.44
After Hours:
227.00
-0.010
-0.00%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $227.01, with a volume of 6.46M.
It is down -0.19% in the last 24 hours and up +2.05% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$227.45
Open:
$227.66
24h Volume:
6.46M
Relative Volume:
0.99
Market Cap:
$401.39B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
96.13
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-2.93%
1M Performance:
+2.05%
6M Performance:
+7.26%
1Y Performance:
+4.78%
1-Day Range:
$226.16
$231.26
1-Week Range:
$223.23
$237.11
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
227.01 | 402.17B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
1,001.35 | 900.48B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.71 | 584.62B | 94.19B | 26.80B | 19.70B | 11.05 |
|
NVS
Novartis Ag Adr
|
161.59 | 310.63B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
194.99 | 302.33B | 58.80B | 10.24B | 8.98B | 3.2788 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
William Blair and BMO Maintain Outperform on AbbVie Inc. (ABBV) March 2026 - Meyka
AbbVie reports ‘positive’ results from Phase 1 study of ABBV-295 - TipRanks
AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 millionSEC filing - marketscreener.com
ICER to review AbbVie’s Parkinson’s disease drug - The Pharma Letter
AbbVie (ABBV) Reports Promising Phase 1 Results for Obesity Trea - GuruFocus
AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss - Benzinga
AbbVie sees promising early-stage data for weight loss asset ABBV-295 - Seeking Alpha
AbbVie Trial Updates Add Context To Valuation And Growth Outlook - Yahoo Finance
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
AbbVie (ABBV) Reports Promising Results from Phase 1 Study of AB - GuruFocus
Gubra's partner AbbVie reports positive phase 1 results for ABBV-295 - marketscreener.com
AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog - TradingView
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults - Yahoo Finance
Streptococcus Market Is Going to Boom | AbbVie • Pfizer • Merck & Co. • GlaxoSmithKline - openPR.com
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease - Insider Monkey
AbbVie Inc. (ABBV) is Drawing Interest from Investors: Key Information You Need to Know - Bitget
AbbVie Stock Analysis: Performance, Financials, and OutlookNews and Statistics - IndexBox
Is AbbVie (ABBV) Still Priced Attractively After Its Strong Multi Year Share Price Run - Yahoo Finance
AbbVie (NYSE:ABBV) SVP David Ryan Purdue Sells 5,230 Shares - MarketBeat
Evercore notes AbbVie Inc.’s (ABBV) Tremfya gains market share, but future earnings growth may be limited - MSN
AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
These 3 Cash Flow Machines Provide Stability in Uncertain Markets - Investing.com
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? - Yahoo Finance
Edgar Lomax Co. VA Reduces Stock Position in AbbVie Inc. $ABBV - MarketBeat
Crossmark Global Holdings Inc. Raises Holdings in AbbVie Inc. $ABBV - MarketBeat
Berry Wealth Group LP Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative? - Yahoo Finance
AbbVie to invest $380 million in North Chicago campus to make next generation medicines - Daily Herald
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Chronic Idiopathic Constipation Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland - Barchart.com
Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating - marketscreener.com
AbbVie (ABBV) Completes $7.75 Billion Notes Offering - GuruFocus
GW&K Investment Management LLC Sells 6,207 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Completes $8 Billion Senior Notes Financing Offering - TipRanks
Immunology, Obesity And Other Insights From The TD Cowen Healthcare Conference - Citeline News & Insights
US287YEG0 Bond Price and Chart — MUN:US287YEG0 - TradingView
Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results - Yahoo Finance
AbbVie: Stabilizes Near $233 While Testing Resistance - Seeking Alpha
AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell - The Globe and Mail
Uterine Fibroid Treatment Drugs Market Is Going to Boom Rapidly | - openPR.com
AbbVie stock price forecast: Stabilizes near $233 while testing resistance - Traders Union
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS - AbbVie News Center
Neurogenic Detrusor Overactivity Market Is Going to Boom Rapidly | Astellas Pharma Inc., Allergan plc (AbbVie Inc.) - openPR.com
Griffith & Werner Inc. Invests $2.64 Million in AbbVie Inc. $ABBV - MarketBeat
Picton Mahoney Asset Management Has $25.14 Million Stake in AbbVie Inc. $ABBV - MarketBeat
How Positive Crohn’s Phase 3 Data for SKYRIZI Could Impact AbbVie (ABBV) Investors - simplywall.st
Dimensional Fund Advisors LP Has $2.06 Billion Position in AbbVie Inc. $ABBV - MarketBeat
Cresset Asset Management LLC Sells 15,199 Shares of AbbVie Inc. $ABBV - MarketBeat
Perry Siatis Sells 18,668 Shares of AbbVie Inc (ABBV) - GuruFocus
AbbVie (ABBV) EVP Roopal Thakkar reports tax-withholding share disposition - Stock Titan
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):